377 related articles for article (PubMed ID: 17988751)
1. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.
Thiemann G; van der Stelt M; Petrosino S; Molleman A; Di Marzo V; Hasenöhrl RU
Behav Brain Res; 2008 Mar; 187(2):289-96. PubMed ID: 17988751
[TBL] [Abstract][Full Text] [Related]
2. Opposing roles of CB
Gobira PH; Oliveira AC; Gomes JS; da Silveira VT; Asth L; Bastos JR; Batista EM; Issy AC; Okine BN; de Oliveira AC; Ribeiro FM; Del Bel EA; Aguiar DC; Finn DP; Moreira FA
Br J Pharmacol; 2019 May; 176(10):1541-1551. PubMed ID: 30101419
[TBL] [Abstract][Full Text] [Related]
3. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.
Lerner TN; Horne EA; Stella N; Kreitzer AC
J Neurosci; 2010 Feb; 30(6):2160-4. PubMed ID: 20147543
[TBL] [Abstract][Full Text] [Related]
5. The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus.
Thiemann G; Di Marzo V; Molleman A; Hasenöhrl RU
Pharmacol Biochem Behav; 2008 May; 89(3):384-91. PubMed ID: 18294680
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation.
Eisenstein SA; Holmes PV; Hohmann AG
Synapse; 2009 Nov; 63(11):941-50. PubMed ID: 19593824
[TBL] [Abstract][Full Text] [Related]
7. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
8. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor.
Pucci M; Pasquariello N; Battista N; Di Tommaso M; Rapino C; Fezza F; Zuccolo M; Jourdain R; Finazzi Agrò A; Breton L; Maccarrone M
J Biol Chem; 2012 May; 287(19):15466-78. PubMed ID: 22431736
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
[TBL] [Abstract][Full Text] [Related]
11. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
12. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Thiemann G; Watt CA; Ledent C; Molleman A; Hasenöhrl RU
Behav Brain Res; 2009 Jun; 200(1):60-7. PubMed ID: 19162082
[TBL] [Abstract][Full Text] [Related]
13. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility.
Maccarrone M; Fride E; Bisogno T; Bari M; Cascio MG; Battista N; Finazzi Agrò A; Suris R; Mechoulam R; Di Marzo V
Mol Hum Reprod; 2005 Jan; 11(1):21-8. PubMed ID: 15563449
[TBL] [Abstract][Full Text] [Related]
16. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.
Spoto B; Fezza F; Parlongo G; Battista N; Sgro' E; Gasperi V; Zoccali C; Maccarrone M
Biochimie; 2006 Dec; 88(12):1889-97. PubMed ID: 16949718
[TBL] [Abstract][Full Text] [Related]
17. Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neurobiol Dis; 2009 Oct; 36(1):70-80. PubMed ID: 19591935
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity.
Patel S; Rademacher DJ; Hillard CJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):880-8. PubMed ID: 12808005
[TBL] [Abstract][Full Text] [Related]
19. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice.
Dubreucq S; Matias I; Cardinal P; Häring M; Lutz B; Marsicano G; Chaouloff F
Neuropsychopharmacology; 2012 Jul; 37(8):1885-900. PubMed ID: 22434220
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake.
Valenti M; Cottone E; Martinez R; De Pedro N; Rubio M; Viveros MP; Franzoni MF; Delgado MJ; Di Marzo V
J Neurochem; 2005 Nov; 95(3):662-72. PubMed ID: 16135090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
